BioCryst Pharmaceuticals BCRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$457.98M-274% | $263.86M+3,106% | -$8.78M+75.4% | -$35.71M+33.2% | -$53.47M+39.8% | ||
| $1.52M+9.4% | $1.39M+6.5% | $1.3M+1.9% | $1.28M+0.7% | $1.27M+2.0% | ||
| $79.73M-6.3% | $85.07M+3.0% | $82.61M+1.7% | $81.26M+11.1% | $73.13M+11.8% | ||
| $5.62M+243% | $1.64M-50.1% | $3.29M+5.5% | $3.12M— | —— | ||
| $30M-48.1% | $57.8M+34.9% | $42.84M— | —— | —— | ||
| $4.16M-46.8% | $7.83M+47.2% | $5.32M— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $23.29M-36.7% | $36.81M+28.7% | $28.61M-10.3% | $31.91M-2.9% | $32.85M+44.7% | ||
| $313.1M-9.9% | $347.37M+592% | $50.2M— | —— | —— | ||
| $2.73M+10.5% | $2.47M+5.4% | $2.34M+122% | $1.06M+2.3% | $1.03M-8.2% | ||
| —— | —— | —— | —— | —— | ||
| $213.48M-18.6% | $262.24M+48.8% | $176.27M+21.9% | $144.56M-36.5% | $227.52M-14.7% | ||
| $401.88M+56.6% | $256.65M-3.4% | $265.65M+16.4% | $228.13M-18.4% | $279.48M-12.8% | ||
| —— | -$6.18M-33.3% | -$4.64M-50.0% | -$3.09M-100% | -$1.55M— | ||
| -$309.44M-2,160% | -$13.69M-116% | $87.59M+6.2% | $82.51M+54.6% | $53.38M-3.0% | ||
| —— | —— | —— | —— | —— | ||
| $26.2M+187% | $9.12M— | —— | —— | —— | ||
| $1.82M-8.6% | $1.99M+3.5% | $1.92M-2.2% | $1.96M+7.3% | $1.83M+7.4% | ||
| $8.68M-1.9% | $8.85M+49.2% | $5.93M+6.6% | $5.56M-14.9% | $6.54M-13.3% | ||
| —— | —— | —— | —— | —— | ||
| $62.09M+118% | -$349.93M-157% | -$135.99M— | —— | —— | ||
| —— | —— | —— | $1.36M+1,036% | -$145K+84.5% | ||
| $66.5M+544% | -$14.99M— | —— | —— | —— | ||
| $20.67M-12.9% | $23.74M-27.9% | $32.93M-11.1% | $37.02M+7.2% | $34.55M+13.7% | ||
| —— | —— | $2.6M+32.1% | $1.97M+38.6% | $1.42M-11.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$2.7M+37.7% | -$4.33M+27.8% | -$6M+18.2% | -$7.33M+24.2% | -$9.68M+15.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | $17.55M+33.3% | $13.16M+50.0% | $8.77M+100% | $4.39M— | ||
| —— | —— | —— | —— | $0— | ||
| —— | $3.57M+33.3% | $2.67M+50.0% | $1.78M+100% | $891.5K— | ||
| $4.16M-46.8% | $7.83M+47.2% | $5.32M— | —— | —— | ||
| $74.51M+8.9% | $68.43M-12.4% | $78.09M-3.6% | $81.01M— | —— | ||
| $921K-12.8% | $1.06M0.0% | $1.06M-55.7% | $2.39M+52.0% | $1.57M+15.4% | ||
| $52.94M-0.4% | $53.16M-0.3% | $53.34M-2.0% | $54.44M— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | -$6.18M-33.3% | -$4.64M-50.0% | -$3.09M-100% | -$1.55M— | ||
| $401.88M+56.6% | $256.65M-3.4% | $265.65M+16.4% | $228.13M-18.4% | $279.48M-12.8% | ||
| $1.82M-8.6% | $1.99M+3.5% | $1.92M-2.2% | $1.96M+7.3% | $1.83M+7.4% | ||
| —— | $15.5M+33.3% | $11.63M+50.0% | $7.75M+100% | $3.88M— | ||
| —— | —— | —— | —— | —— | ||
| $26.2M+187% | $9.12M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $23.36M+2.1% | $22.88M+39.5% | $16.41M+315% | $3.96M— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $1.2M-24.9% | ||
| —— | —— | —— | $912K— | —— | ||
| $310.37M-10.0% | $344.9M+621% | $47.86M— | —— | —— | ||
| $310.37M-10.0% | $344.9M+621% | $47.86M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does BioCryst Pharmaceuticals generate?
- BioCryst Pharmaceuticals (BCRX) generated $313.1M in operating cash flow over the trailing twelve months.
- What is BioCryst Pharmaceuticals's free cash flow?
- After $2.7M of capital expenditures, BioCryst Pharmaceuticals's free cash flow was $310.4M over the trailing twelve months, up 448.8% year over year.
- Where does BioCryst Pharmaceuticals's cash flow data come from?
- Every line is extracted from BioCryst Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
